Efficacy and safety of dupilumab in two adolescents with severe atopic dermatitis.

ABSTRACT: We report the cases of two adolescent siblings with severe atopic dermatitis, who, despite weighing approximately 40kg, presented a good response to dupilumab with the off-label dose for individuals aged 12 years and weighing 60kg. Both had already used cyclosporine, azathioprine, methotrexate and oral corticosteroids for long periods, plus topical treatments with no adequate disease control. Skin lesions were constant and widespread, with frequent skin infections and very poor quality of life, with numerous physical and psychosocial consequences, such as dropping out of school activities due to severe itching, appearance and bullying. They also showed delayed growth and development. In 2018, dupilumab, an immunobiological agent, was approved for treatment of moderate to severe atopic derm

SUBMITTER: Giavina-Bianchi M 

PROVIDER: S-EPMC8081439 | biostudies-literature | 2021

REPOSITORIES: biostudies-literature